Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation

The Nazareth Hospital, Israel42 enrolled

Overview

Corticosteroid treatment in diabetic patients admitted for COPD exacerbation are expected to significantly increase hemoglobin A1C levels

HbA1C levels were evaluated in diabetic patients with COPD exacerbation on admission to the hospital and 3-months later. Demographic, clinical, laboratory variables and total steroid dose were documented. Age- and sex-matched group of diabetic patients with COPD who were admitted for other reasons, were asked to participate as a control group. Mann-Whitney and Chi square/Fischer's exact tests were used to compare between the parameters of the two groups. Wilcoxon signed rank test was used to compare between HbA1C levels at baseline and 3 months later. Multi-variate linear regression analysis was used to find predictors for increase in HbA1C levels in the patients' group.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes Chronic Obstructive Pulmonary Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetic patients with COPD exacerbation Exclusion Criteria: * Patients treated with steroids during the previous 3 months

Locations (1)

Department of medicine

Nzareth, Nazareth, Israel

Outcomes

Primary Outcomes

Hemoglobin A1C LEVEL

Time frame: 3 MONTHS

Secondary Outcomes

Glucose levels

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.